New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 11, 2014
06:02 EDTTTHITransition Therapeutics appoints Carl Damiani as COO
Transition Therapeutics announced that Carl Damiani has been appointed to the role of COO of Transition. Since joining Transition in 2003, Damiani has held the roles of vice-president of Business Development and Director of Business Development.
News For TTHI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
06:04 EDTTTHITransition Therapeutics announces results from two Phase 1 studies of ELND005
Subscribe for More Information
06:03 EDTTTHITransition Therapeutics announces results from Phase 1 AME study of ELND005
Transition Therapeutic announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion study and a renal clearance study, are specialized clinical pharmacology trials that are required by the FDA for the approval of most drugs in development. The AME study enrolled 8 subjects and the renal clearance study enrolled 42 subjects. In both studies, ELND005 showed good safety and tolerability. The key result of the AME study was that ELND005 showed good oral bioavailability as there was nearly 100% absorption. ELND005 showed no evidence of hepatic or intermediary metabolism and the study demonstrated that the main excretion route of ELND005 is via the kidney. These AME properties of good oral bioavailability, low protein binding, and lack of CYP metabolism are usually associated with consistent plasma levels and with a reduced risk of drug-drug interactions. The AME profile of ELND005 is well suited for an Alzheimer's disease patient population that is commonly administered multiple concomitant medications, many of which are metabolized by the liver. The renal clearance study evaluated the pharmacokinetic profile of ELND005 in subjects with various degrees of renal impairment. In this study, ELND005 showed minimal protein binding in plasma regardless of renal function. Across the 5 study arms, subjects with worse renal function had increased plasma drug exposure compared to those with normal renal function. The study provided important guidance for the minimum creatinine clearance needed to allow patient participation in studies with a fixed dose regimen of ELND005. This minimum creatinine clearance is consistent with the threshold used as exclusion criterion in the ongoing study of ELND005 in Agitation and Aggression of AD.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use